Dr. Alfred Slanetz currently serves as a Director of the Board of the the National Foundation for Cancer Research (NFCR).  He is the founder, president, and chief executive officer of Geneius Biotechnology, Inc. (Geneius) and has been since its incorporation. He also has served as a director on Geneius’s board since its incorporation in 2012.

Bachelor of Science in Biology, Hamilton College
Master of Science in Biomedical Engineering, Brown University
Ph.D. in Molecular and Immunology, Yale University

Geneius, an immuno-oncology start-up, is researching ways to help cancer patients’ immune systems detect and attack cancer cells. This new therapy is dubbed Targeted Diversity and when combined with surgery, it promises to change the difficult process or surgery, drugs and radiation that is the current standard.

Between 2006 and 2011 Dr. Slanetz was President and CEO at Bluebird Bio. He served as President and CEO of Genetix Pharmaceuticals, Inc. He served as Vice President, Business Development of TRANSGENE in May 1996. From 1994 to 1996, he served as Manager, New Product Planning and Development at Genentech Inc. Prior to that, Dr. Slanetz was a Management Consultant for Arthur D. Little.

In 1993 Dr. Slanetz received his Ph.D. in Molecular and Immunobiology from Yale University. He earned his Master of Science in Biomedical Engineering from Brown University in 1986. He holds a Bachelor of Science in Biology from Hamilton College.